Detalhe da pesquisa
1.
MS4A3 promotes differentiation in chronic myeloid leukemia by enhancing common ß-chain cytokine receptor endocytosis.
Blood
; 139(5): 761-778, 2022 02 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34780648
2.
Identification of genetic targets in acute myeloid leukaemia for designing targeted therapy.
Br J Haematol
; 192(1): 137-145, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33022753
3.
Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors.
Haematologica
; 104(12): 2400-2409, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31073075
4.
shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance.
Blood
; 125(11): 1772-81, 2015 Mar 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-25573989
5.
An ex vivo investigation of interactions between primary acute myeloid leukaemia and mesenchymal stromal cells yields novel therapeutic targets.
Br J Haematol
; 190(4): e236-e239, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32519342
6.
BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships.
Blood
; 121(3): 489-98, 2013 Jan 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-23223358
7.
Development of artificial bone marrow fibre scaffolds to study resistance to anti-leukaemia agents.
Br J Haematol
; 182(6): 924-927, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28771682
8.
Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy.
Blood
; 117(14): 3733-6, 2011 Apr 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-21346253
9.
FISH-negative BCR::ABL1-positive e19a2 chronic myeloid leukaemia: the most cryptic of insertions.
BMC Med Genomics
; 16(1): 172, 2023 07 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-37496024
10.
Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy.
Blood
; 116(25): 5497-500, 2010 Dec 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-20833982
11.
Advances in the treatment of chronic myeloid leukemia.
BMC Med
; 9: 99, 2011 Aug 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-21867560
12.
Genomic Abnormalities as Biomarkers and Therapeutic Targets in Acute Myeloid Leukemia.
Cancers (Basel)
; 13(20)2021 Oct 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34680203
13.
A Role for the Bone Marrow Microenvironment in Drug Resistance of Acute Myeloid Leukemia.
Cells
; 10(11)2021 10 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-34831055
14.
Carfilzomib Enhances the Suppressive Effect of Ruxolitinib in Myelofibrosis.
Cancers (Basel)
; 13(19)2021 Sep 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-34638347
15.
Proteasome 26S subunit, non-ATPases 1 (PSMD1) and 3 (PSMD3), play an oncogenic role in chronic myeloid leukemia by stabilizing nuclear factor-kappa B.
Oncogene
; 40(15): 2697-2710, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33712704
16.
SIRT5 IS A DRUGGABLE METABOLIC VULNERABILITY IN ACUTE MYELOID LEUKEMIA.
Blood Cancer Discov
; 2(3): 266-287, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34027418
17.
European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor.
Blood
; 112(12): 4437-44, 2008 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18716134
18.
Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia.
Haematologica
; 95(2): 224-31, 2010 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-19833633
19.
Molecular Monitoring of Chronic Myeloid Leukemia.
Methods Mol Biol
; 2065: 153-173, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-31578694
20.
The KDR (VEGFR-2) Genetic Polymorphism Q472H and c-KIT Polymorphism M541L Are Associated With More Aggressive Behaviour in Astrocytic Gliomas.
Cancer Genomics Proteomics
; 17(6): 715-727, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33099473